

references. The present invention therefore, must be viewed as patentable over the cited prior art.

The following shows the status of the pending claims.

In the Claims:

No amendment is made to the claims. Claims 1-24 remain pending.

Amendment/Response -2-
S.N. 09/555,987
P27-017.January2005responseafter final

1. (Previously presented) A method of treating type II diabetes mellitus symptoms of glucose intolerance and elevated plasma insulin in an animal, said method comprising administering to said animal a therapeutically effective amount of conjugated linoleic acid, said method producing enhanced glucose tolerance and reduced plasma insulin levels in said animal.
2. (Original) The method of claim 1, wherein said conjugated linoleic acid is administered orally.
3. (Original) The method of claim 2, wherein said conjugated linoleic acid is administered in a unit dosage form.
4. (Original) The method of claim 3, wherein said unit dosage form is a food product.
5. (Original) The method of claim 1, wherein said conjugated linoleic acid is selected from the group consisting of 9,11-octadecadienoic acid, esters thereof, geometric isomers thereof, salts thereof and mixtures thereof.
6. (Original) The method of claim 5, wherein said geometric isomers have configurations selected from the group consisting of trans,trans; cis,cis; trans,cis; and cis,trans.
7. (Original) The method of claim 1, wherein said conjugated linoleic acid is selected from the group consisting of 10,12-octadecadienoic acid, esters thereof, geometric isomers thereof, salts thereof and mixtures thereof.
8. (Original) The method of claim 7, wherein said geometric isomers have configurations selected from the group consisting of trans,trans; cis,cis; trans,cis; and cis,trans.
9. (Previously presented) The method of claim 1, wherein said conjugated linoleic acid is

Amendment/Response

-3-

S.N. 09/555,987

P27-017.January2005response after final

comprised predominantly of cis,trans-9,11-octadecadienoic acid and trans,cis-octadecadienoic acid.

10. (Previously presented) The method of claim 1, wherein said conjugated linoleic acid is comprised predominantly of cis,cis-9,11-octadecadienoic acid.

11. (Original) The method of claim 1, wherein said conjugated linoleic acid is administered in an amount of about 1 mg of said conjugated linoleic acid/kg body weight to about 10,000 mg of said conjugated linoleic acid/kg body weight.

12. (Original) The method of claim 1, wherein said animal is a mammal.

13. (Original) The method of claim 12, wherein said mammal is a human.

14. (Original) The method of claim 1, wherein said conjugated linoleic acid is administered in a pharmaceutically acceptable carrier medium.

15. (Original) The method of claim 14, wherein said pharmaceutically acceptable carrier medium includes water.

16-21.. Cancelled.

22. (Previously presented) A method of treating symptoms of glucose intolerance and elevated plasma insulin in a human with type II diabetes mellitus comprising:

a) providing

- i) a therapeutically effective amount of conjugated linoleic acid; and
- ii) a human patient with type II diabetes mellitus; and

b) administering said therapeutically effective amount of conjugated linoleic acid to said

Amendment/Response

-4-

S.N. 09/555,987

P27-017.January2005response after final

human diabetic patient under conditions such that said symptoms are treated by normalizing glucose tolerance and reducing plasma insulin and glucose levels.

23. (Previously presented) The method of claim 1 wherein said symptoms further includes elevated glucose levels.

24. (Previously presented) The method of claim 22 wherein said symptoms further includes elevated glucose levels.

Amendment/Response -5-
S.N. 09/555,987
P27-017.January2005responseafter final